Literature DB >> 20924191

Annexin-1 downregulation is associated with clinical outcome in Chinese patients with hilar cholangiocarcinoma.

D Wang1, H Zhang, Z Fang, G Yu.   

Abstract

AIMS: Annexin A1 (ANXA1) is a calcium- and phospholipid-binding protein and has been implicated in regulating inflammatory responses, cell proliferation and apoptosis. The evidence of its importance in carcinogenesis increased rapidly. However, the status of ANXA1 in hilar cholangiocarcinoma remains unclear. Here, we detected ANXA1 expression and determined its clinical significance in Chinese patients with hilar cholangiocarcinoma.
METHODS: Tissue microarray blocks containing tumor specimens obtained from 61 patients were constructed. Expression of ANXA1 in these specimens was analyzed using immunohistochemical studies.
RESULTS: ANXA1 expression was observed in 27 cases (44.3%). Loss of ANXA1 expression was significantly associated with lymph node metastases and histopathologic grade. ANXA1 expression has a significant inverse correlation with recurrence and poor survival in univariate analyses.Multivariate analyses revealed that loss of ANXA1 expression was an independent predictor for future recurrence and overall survival in patients with cholangiocarcinoma.
CONCLUSIONS: Decreased expression of ANXA1 is a common event in human hilar cholangiocarcinoma and is significantly correlated with the poor outcome of patients with cholangiocarcinoma, suggesting a potential role of ANXA1 in cancer development and progression.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924191     DOI: 10.1159/000320237

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  9 in total

1.  Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma.

Authors:  Dongyun Xu; Wei Yi; Ying Chen; Lijun Ma; Jiejun Wang; Guanzhen Yu
Journal:  Med Oncol       Date:  2014-10-26       Impact factor: 3.064

2.  Loss of MTSS1 expression is an independent prognostic factor for Hilar cholangiocarcinoma.

Authors:  Fei Wang; Yulong Liu; Hao Zhang
Journal:  Pathol Oncol Res       Date:  2013-07-14       Impact factor: 3.201

3.  Association of nuclear annexin A1 with prognosis of patients with esophageal squamous cell carcinoma.

Authors:  Gaohua Han; Ye Tian; Bensong Duan; Haihui Sheng; Hengjun Gao; Junxing Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

4.  Annexin A1: A new immunohistological marker of cholangiocarcinoma.

Authors:  Nuttanan Hongsrichan; Rucksak Rucksaken; Yaovalux Chamgramol; Porntip Pinlaor; Anchalee Techasen; Puangrat Yongvanit; Narong Khuntikeo; Chawalit Pairojkul; Somchai Pinlaor
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

5.  SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.

Authors:  Yang Yu; Yan Chen; Jianxia Ma; Xiaofeng Yu; Guanzhen Yu; Zhaoshen Li
Journal:  Tumour Biol       Date:  2015-10-21

6.  FOXK1 plays an oncogenic role in the progression of hilar cholangiocarcinoma.

Authors:  Yujie Feng; Zhigang Bai; Jianning Song; Zhongtao Zhang
Journal:  Mol Med Rep       Date:  2020-12-10       Impact factor: 2.952

7.  Annexin Expression in Cholangiocarcinoma, and Metastatic Pancreatic Ductal Adenocarcinoma "Is it be Helpful for Differential Diagnosis of These Tumors in the Liver?"

Authors:  Bita Geramizadeh; Mahsa Sehat; Azam Mehrmozayan; Ali Reza Ali Reza
Journal:  Iran J Pathol       Date:  2021-07-06

Review 8.  Pathobiological functions and clinical implications of annexin dysregulation in human cancers.

Authors:  Llara Prieto-Fernández; Sofía T Menéndez; María Otero-Rosales; Irene Montoro-Jiménez; Francisco Hermida-Prado; Juana M García-Pedrero; Saúl Álvarez-Teijeiro
Journal:  Front Cell Dev Biol       Date:  2022-09-28

9.  Differential expression of ANXA1 in benign human gastrointestinal tissues and cancers.

Authors:  Yunshu Gao; Ying Chen; Dongyun Xu; Jiejun Wang; Guanzhen Yu
Journal:  BMC Cancer       Date:  2014-07-19       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.